Corium International competitors

Corium International Competitors include Reata Pharmaceuticals, Ironwood Pharmaceuticals, Biogen and MyoKardia.
Add company...
Corium International
Corium International
Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Biogen
Biogen
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Founding Date
Founding Date
1999
Founding Date
2002
Founding Date
N/A
Founding Date
1978
Founding Date
2012
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Menlo Park, US HQ
Kentwood, US
Locations
Irving, US HQ
Locations
Cambridge, US HQ
Locations
Cambridge, US HQ
Locations
South San Francisco, US HQ
Employees
Employees
213
Employees
12332% increase
Employees
730
Employees
7,8007% increase
Employees
1024% increase
Valuation ($)
Valuation ($)
463 m
Valuation ($)
N/A
Valuation ($)
2.1 b
Valuation ($)
42.6 b
Valuation ($)
2.2 b
Twitter followers
Twitter followers
N/A
Twitter followers
418
Twitter followers
3.1 k
Twitter followers
19.4 k
Twitter followers
387

Financial

Revenue (est.)
Revenue (est.)
$31.9m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$346.6m (FY, 2018)
Revenue (est.)
$11.4b (FY, 2016)
Revenue (est.)
N/A
Net income
Net income
N/A
Net income
($80.5m) (FY, 2018)
Net income
($282.4m) (FY, 2018)
Net income
$3.7b (FY, 2016)
Net income
($67.7m) (FY, 2018)

Operating

Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
4 (FY, 2016)
Phase I Trials Products
2 (FY, 2017)
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
10 (FY, 2016)
Phase II Trials Products
1 (FY, 2017)
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A

Funding

Total funding raised
Total funding raised
$ 40m
Total funding raised
$ 300m
Total funding raised
$ 284m
Total funding raised
N/A
Total funding raised
$ 98m
For sources of this data, please see the company profileDownload Excel

View company profiles

Reata Pharmaceuticals
HQ
Irving, US
Employees
123↑ 32% increase

Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.

View company
Ironwood Pharmaceuticals
HQ
Cambridge, US
Employees
730

Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.

View company
Biogen
HQ
Cambridge, US
Employees
7,800↑ 7% increase

Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.

View company
MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company